The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

A new drug could change everything for children like seven-year-old Liliana, who has Prader-Willi syndrome, a rare genetic ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS). IPWSO hopes the US FDA approval is the ...

US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...

Initiation of the Phase 2 EMPOWER trial of ARD-201 for the treatment of obesity and obesity-related conditions as a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor is ...

Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...

Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Aardvark Therapeutics, Inc.’s AARD share price has surged by 12.79%, which has investors questioning if this is right time to sell.